GOLM1 and cancer: The multiple factors involved in the resistance of cancer cells to methotrexate also participate in complex extracellular signal pathways, e.g., GOLM1 is a positive regulator of the PI3K/AKT pathway, and the PI3K inhibitor BKM120 abrogates the function of GOLM1 during the oncogenic process [35].